Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single‐centre experience in patients with BRAF‐mutated melanoma

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

(2019) Bastian Schilling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

(2019) Sophia Kreft et al.   EUROPEAN JOURNAL OF CANCER

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

(2018) Sara Valpione et al.   EUROPEAN JOURNAL OF CANCER

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

(2018) Caroline Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

(2018) Reinhard Dummer et al.   LANCET ONCOLOGY

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma

(2018) Samuel Rosner et al.   Cancer Medicine

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

(2017) Dirk Schadendorf et al.   EUROPEAN JOURNAL OF CANCER

Sequencing Treatment in BRAFV600 Mutant Melanoma

(2017) Douglas B. Johnson et al.   JOURNAL OF IMMUNOTHERAPY

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

Dabrafenib plus trametinib in patients with BRAF V600 -mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

(2017) Michael A Davies et al.   LANCET ONCOLOGY

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF V600 -mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial

(2017) Max Schreuer et al.   LANCET ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

(2017) Ester Simeone et al.   OncoImmunology

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

(2016) Benjamin Weide et al.   CLINICAL CANCER RESEARCH

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

(2016) Michael B. Atkins et al.   JNCI-Journal of the National Cancer Institute

NCCN Guidelines Insights: Melanoma, Version 3.2016

(2016) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

(2016) Paolo A Ascierto et al.   LANCET ONCOLOGY

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

(2016) Georgina V Long et al.   LANCET ONCOLOGY

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives

(2016) Michael B. Atkins et al.   JNCI-Journal of the National Cancer Institute

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) R. Dummer et al.   ANNALS OF ONCOLOGY

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression

(2015) A. Scholtens et al.   EUROPEAN JOURNAL OF CANCER

BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma

(2015) S. D. Bradley et al.   Cancer Immunology Research

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

(2014) Allison Ackerman et al.   CANCER

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

(2013) M. K. Callahan et al.   Cancer Immunology Research

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH